Global Formulation Development Outsourcing Market Overview

Global Formulation Development Outsourcing Market was valued at USD 20.15 Billion in 2021 and is expected to reach USD 33.08 Billion by the year 2028, at a CAGR of 7.34%.

The increasing trend of major drugs' patent protection expiration and the rising number of pharmaceutical and biopharmaceutical companies that are outsourcing their services are expected to fuel the growth of the formulation development outsourcing market, worldwide. For instance, Cancer Research UK has initiatives to promote small molecule drug discovery. It runs a program known as the "Small Molecule Drug Discovery Project Award" and invests in milestone-driven projects at all stages of drug discovery, from target identification/validation to early preclinical studies. It provides funding support for around 12-36 months, with an amount of GBP 100,000 annually.

Additionally, major biopharmaceutical companies are collaborating with outsourcing services in the early phase of drug development to overcome risks and save time and money involved in the process of passing the drug through the development pipeline. Furthermore, with increasing collaborations between contract manufacturing organizations (CMOs)/contract development and manufacturing organizations (CDMOs) and pharmaceutical companies, the market studied is expected to thrive over the forecast period. Moreover, the emergence of COVID-19 and the development of novel therapeutics for the same may also accelerate the market growth over the forecast period. However, insufficient funding to carry out drug development research and structural changes in the pharmaceutical industry may limit the growth of the market studied.

COVID-19 Impact on Formulation Development Outsourcing Market

The ongoing COVID-19 pandemic has slowed down various drug discovery processes, owing to the halting of various clinical trials. However, on a brighter note, pharmaceutical companies can expect generous incentives to invest in developing drugs and vaccines against infectious diseases. Public health challenges about oncology, heart diseases, and many other rare conditions still exist. Hence, clinical research must go on. Thus, outsourcing is expected to increase in the upcoming period. With an urgent need for an effective vaccine/drug, companies are increasingly opting for formulation development outsourcing to enhance their clinical trials, which may boost market growth over the next few years.

Market Dynamics And Factors

Drivers:

The Growing Number Of Pharmaceutical And Biopharmaceutical Companies Outsourcing Their Services

With the increasing demand for generic medicines and biologics, the capital-concerted nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in entering a contract with a CMO (contract manufacturing outsourcing) for formulation development.

Pharmaceutical companies are moderately outsourcing R&D activities to academic and private contract research organizations (CROs) to minimize drug development timelines and costs. As per the article published in 2018, which was titled "The Era of Pharma and Biotech Outsourcing", an estimated 75.0-80.0% of R&D spending in the biopharmaceutical industry can be outsourced, creating opportunities for CROs. This factor, in turn, may boost market growth.

Contract research and production companies are funding personnel, infrastructure, and technology to purchase a significant share of the healthcare outsourcing market. The rising number of end-to-end service suppliers focusing to meet the growing demand for cheaper-cost drug development and production is expected to accelerate the market growth.

Pharmaceutical companies are collaborating with formulation development outsourcing firms in developing countries owing to the accessibility of skilled and low-cost workforce and quality data. Cost-reduction, developing innovation, reaching access to particular knowledge and technology, and rising speed and agility are some of the significant factors motivating pharma companies to extend the level of formulation development outsourcing. Hence, due to these factors, the market is expected to grow during the forecast period.

Restraints:

Another key factor restraining the market growth is structural changes in the pharmaceutical industry. Several changes had taken place in the global pharmaceutical marketplace over the last decade. Such changes have been putting pressure on the large research and development (R&D)-based pharmaceutical transnational corporations (TNCs) to change the way they conduct their businesses. Other pressures have also come to bear on the large R&D-based TNCs, including regulatory and antitrust issues. Regulatory hurdles have risen, with more questions being asked by drug regulatory authorities on the clinical data submitted concerning potential blockbusters.

The number of hurdles blocking access to the European marketplace has also risen. Government authorities have increased their scrutiny of business practices of the large R&D-based pharmaceutical TNCs. The EU antitrust authorities organized four separate but related antitrust raids on large pharmaceutical companies in 2008-2009. In the United States, the antitrust pendulum has swung both for and against deals between R&D-based TNCs and generic firms. However, nowadays, it is probably resisting such deals despite the legal uncertainty of patent litigation in the country. Altogether, this has put great pressure on newly patented product pipelines. Such structural changes are likely to hamper market growth in upcoming years.

Opportunities:

The formulation development outsourcing market is expected to witness healthy growth in the coming years owing to the increasing need for the development of novel therapeutics in the market. As there has been an increasing focus on the development of numerous therapeutics aimed towards providing effective treatment for varied chronic diseases by major pharmaceutical and biopharmaceutical companies, the need for formulation development services is expected to propel in the future as outsourcing is a viable option for these manufacturers. With the blockbuster drugs on the way to their patent expiry, the companies are expected to be striving toward the development of innovative products, which is expected to gain traction for the outsourcing of formulation development.

Market Segmentation

Segmentation Insights

By Service, the formulation optimization segment dominated the market studied, with a revenue of USD 14,016.40 million in 2020, and it is expected to register a high CAGR over the forecast period. Pre-formulation activities are the most crucial part and essential component of the drug development process. It delivers the scientific basis for formulation development. The injectable products are generally presented in vials in the liquid form, providing ease of use in the clinical setting. The growing incidence of chronic diseases, along with rising product approval are the major factors for the growth of the studied segment.

Regional Insights

North America is expected to dominate the overall market over the forecast period. Asia-Pacific is expected to witness the highest CAGR of 9.07% over the forecast period. The United States Formulation Development market is anticipated to witness tremendous growth in the studied market, owing to the growing burden of chronic diseases and the presence of key players in the country. The regional market is turned by the presence of a well-established healthcare system and the growing prevalence of chronic diseases & the requirements for drug development.

The European region shows sluggish growth because of well-stabilized industries, less demand, smart development, and its already developed countries. In upcoming years, the situation will change owing to technological development and fast economic growth will drive the market in the projected period. Another factor for formulation development outsourcing market growth is the rising demand in the European market by pharmaceutical companies for the outsourcing of formulation development activities. This is happening as a consequence of the many efforts that are being made in the market to reduce expenses incurred due to formulation development activities that would increase profitability.

The market for formulation development outsourcing is growing in China, which can be attributed to the increasing prevalence of chronic diseases, the rising number of pharmaceutical and biopharmaceutical companies outsourcing their services, and the rising involvement of the government in strengthening the country's biotech industry. The rising disease burned is pushing pharmaceutical companies to develop novel drugs, which will further boost the overall market growth of the APAC region.

Key Industry Developments

• In February 2021, Quotient Biosciences purchased Arcinova, the UK-based multiservice contract development and manufacturing organization (CDMO), to extend Quotient Biosciences' service portfolio, with the integration of drug substance, drug product, and clinical testing capabilities into its already added pharma services segments.
• In February 2021, Catalent Inc. completed the procedure for the accession of the production and packaging operations of Acorda Therapeutics Inc. The acquisition helps to the expansion of Catalent as a key US-based partner for companies over dry powder inhaled dosage forms.

Players Covered in Formulation Development Outsourcing market are :

• Charles River Laboratories International Inc.
• Aizant Drug Research Solutions Pvt Limited
• Catalent Inc.
• Laboratory Corporation of America Holdings
• Biocon Limited (Syngene International)
• IRISYS LLC
• Intertek Group PLC
• Piramal Enterprises Ltd
• Quotient Sciences
• Thermo Fisher Scientific Inc. (Patheon)
• Emergent BioSolutions Inc.
• Lonza Group AG
• Aurigene Pharmaceutical Services Ltd
• PCI Pharma Services
• Hermes Pharma
• Pyramid Laboratories Inc and  other Major players. 

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Service
 3.2 By Application
 3.3 By Dosage Form

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Formulation Development Outsourcing Market by Service
 5.1 Formulation Development Outsourcing Market Overview Snapshot and Growth Engine
 5.2 Formulation Development Outsourcing Market Overview
 5.3 Pre-Formulation Services
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Pre-Formulation Services: Grographic Segmentation
 5.4 Formulation Optimization
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Formulation Optimization: Grographic Segmentation

Chapter 6: Formulation Development Outsourcing Market by Application
 6.1 Formulation Development Outsourcing Market Overview Snapshot and Growth Engine
 6.2 Formulation Development Outsourcing Market Overview
 6.3 Oncology
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Oncology: Grographic Segmentation
 6.4 Genetic Disorders
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Genetic Disorders: Grographic Segmentation
 6.5 Neurology
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Neurology: Grographic Segmentation
 6.6 Infectious Diseases
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Infectious Diseases: Grographic Segmentation
 6.7 Respiratory
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Respiratory: Grographic Segmentation
 6.8 Cardiovascular
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size (2016-2028F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 Cardiovascular: Grographic Segmentation
 6.9 Others
  6.9.1 Introduction and Market Overview
  6.9.2 Historic and Forecasted Market Size (2016-2028F)
  6.9.3 Key Market Trends, Growth Factors and Opportunities
  6.9.4 Others: Grographic Segmentation

Chapter 7: Formulation Development Outsourcing Market by Dosage Form
 7.1 Formulation Development Outsourcing Market Overview Snapshot and Growth Engine
 7.2 Formulation Development Outsourcing Market Overview
 7.3 Injectable
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Injectable: Grographic Segmentation
 7.4 Oral
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Oral: Grographic Segmentation
 7.5 Topical
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Topical: Grographic Segmentation
 7.6 Other
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Other: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Formulation Development Outsourcing Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Formulation Development Outsourcing Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Formulation Development Outsourcing Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 CHARLES RIVER LABORATORIES INTERNATIONAL INC.
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED
 8.4 CATALENT INC.
 8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
 8.6 BIOCON LIMITED (SYNGENE INTERNATIONAL)
 8.7 IRISYS LLC
 8.8 INTERTEK GROUP PLC
 8.9 PIRAMAL ENTERPRISES LTD
 8.10 QUOTIENT SCIENCES
 8.11 THERMO FISHER SCIENTIFIC INC. (PATHEON)
 8.12 EMERGENT BIOSOLUTIONS INC.
 8.13 LONZA GROUP AG
 8.14 AURIGENE PHARMACEUTICAL SERVICES LTD
 8.15 PCI PHARMA SERVICES
 8.16 HERMES PHARMA
 8.17 PYRAMID LABORATORIES INC
 8.18 OTHER MAJOR PLAYERS

Chapter 9: Global Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Service
  9.2.1 Pre-Formulation Services
  9.2.2 Formulation Optimization
 9.3 Historic and Forecasted Market Size By Application
  9.3.1 Oncology
  9.3.2 Genetic Disorders
  9.3.3 Neurology
  9.3.4 Infectious Diseases
  9.3.5 Respiratory
  9.3.6 Cardiovascular
  9.3.7 Others
 9.4 Historic and Forecasted Market Size By Dosage Form
  9.4.1 Injectable
  9.4.2 Oral
  9.4.3 Topical
  9.4.4 Other

Chapter 10: North America Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Service
  10.4.1 Pre-Formulation Services
  10.4.2 Formulation Optimization
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Oncology
  10.5.2 Genetic Disorders
  10.5.3 Neurology
  10.5.4 Infectious Diseases
  10.5.5 Respiratory
  10.5.6 Cardiovascular
  10.5.7 Others
 10.6 Historic and Forecasted Market Size By Dosage Form
  10.6.1 Injectable
  10.6.2 Oral
  10.6.3 Topical
  10.6.4 Other
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Service
  11.4.1 Pre-Formulation Services
  11.4.2 Formulation Optimization
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Oncology
  11.5.2 Genetic Disorders
  11.5.3 Neurology
  11.5.4 Infectious Diseases
  11.5.5 Respiratory
  11.5.6 Cardiovascular
  11.5.7 Others
 11.6 Historic and Forecasted Market Size By Dosage Form
  11.6.1 Injectable
  11.6.2 Oral
  11.6.3 Topical
  11.6.4 Other
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Service
  12.4.1 Pre-Formulation Services
  12.4.2 Formulation Optimization
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Oncology
  12.5.2 Genetic Disorders
  12.5.3 Neurology
  12.5.4 Infectious Diseases
  12.5.5 Respiratory
  12.5.6 Cardiovascular
  12.5.7 Others
 12.6 Historic and Forecasted Market Size By Dosage Form
  12.6.1 Injectable
  12.6.2 Oral
  12.6.3 Topical
  12.6.4 Other
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Service
  13.4.1 Pre-Formulation Services
  13.4.2 Formulation Optimization
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Oncology
  13.5.2 Genetic Disorders
  13.5.3 Neurology
  13.5.4 Infectious Diseases
  13.5.5 Respiratory
  13.5.6 Cardiovascular
  13.5.7 Others
 13.6 Historic and Forecasted Market Size By Dosage Form
  13.6.1 Injectable
  13.6.2 Oral
  13.6.3 Topical
  13.6.4 Other
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Formulation Development Outsourcing Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Service
  14.4.1 Pre-Formulation Services
  14.4.2 Formulation Optimization
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Oncology
  14.5.2 Genetic Disorders
  14.5.3 Neurology
  14.5.4 Infectious Diseases
  14.5.5 Respiratory
  14.5.6 Cardiovascular
  14.5.7 Others
 14.6 Historic and Forecasted Market Size By Dosage Form
  14.6.1 Injectable
  14.6.2 Oral
  14.6.3 Topical
  14.6.4 Other
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. FORMULATION DEVELOPMENT OUTSOURCING MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. FORMULATION DEVELOPMENT OUTSOURCING MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. FORMULATION DEVELOPMENT OUTSOURCING MARKET COMPETITIVE RIVALRY
TABLE 005. FORMULATION DEVELOPMENT OUTSOURCING MARKET THREAT OF NEW ENTRANTS
TABLE 006. FORMULATION DEVELOPMENT OUTSOURCING MARKET THREAT OF SUBSTITUTES
TABLE 007. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY SERVICE
TABLE 008. PRE-FORMULATION SERVICES MARKET OVERVIEW (2016-2028)
TABLE 009. FORMULATION OPTIMIZATION MARKET OVERVIEW (2016-2028)
TABLE 010. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY APPLICATION
TABLE 011. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 012. GENETIC DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 013. NEUROLOGY MARKET OVERVIEW (2016-2028)
TABLE 014. INFECTIOUS DISEASES MARKET OVERVIEW (2016-2028)
TABLE 015. RESPIRATORY MARKET OVERVIEW (2016-2028)
TABLE 016. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY DOSAGE FORM
TABLE 019. INJECTABLE MARKET OVERVIEW (2016-2028)
TABLE 020. ORAL MARKET OVERVIEW (2016-2028)
TABLE 021. TOPICAL MARKET OVERVIEW (2016-2028)
TABLE 022. OTHER MARKET OVERVIEW (2016-2028)
TABLE 023. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 024. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 025. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 026. N FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 027. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 028. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 029. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 030. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 031. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 032. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 033. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 034. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 038. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 039. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 040. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 041. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 042. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 043. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: SNAPSHOT
TABLE 044. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: BUSINESS PERFORMANCE
TABLE 045. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 046. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: SNAPSHOT
TABLE 047. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: BUSINESS PERFORMANCE
TABLE 048. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: PRODUCT PORTFOLIO
TABLE 049. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. CATALENT INC.: SNAPSHOT
TABLE 050. CATALENT INC.: BUSINESS PERFORMANCE
TABLE 051. CATALENT INC.: PRODUCT PORTFOLIO
TABLE 052. CATALENT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. LABORATORY CORPORATION OF AMERICA HOLDINGS: SNAPSHOT
TABLE 053. LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS PERFORMANCE
TABLE 054. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 055. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOCON LIMITED (SYNGENE INTERNATIONAL): SNAPSHOT
TABLE 056. BIOCON LIMITED (SYNGENE INTERNATIONAL): BUSINESS PERFORMANCE
TABLE 057. BIOCON LIMITED (SYNGENE INTERNATIONAL): PRODUCT PORTFOLIO
TABLE 058. BIOCON LIMITED (SYNGENE INTERNATIONAL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. IRISYS LLC: SNAPSHOT
TABLE 059. IRISYS LLC: BUSINESS PERFORMANCE
TABLE 060. IRISYS LLC: PRODUCT PORTFOLIO
TABLE 061. IRISYS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. INTERTEK GROUP PLC: SNAPSHOT
TABLE 062. INTERTEK GROUP PLC: BUSINESS PERFORMANCE
TABLE 063. INTERTEK GROUP PLC: PRODUCT PORTFOLIO
TABLE 064. INTERTEK GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. PIRAMAL ENTERPRISES LTD: SNAPSHOT
TABLE 065. PIRAMAL ENTERPRISES LTD: BUSINESS PERFORMANCE
TABLE 066. PIRAMAL ENTERPRISES LTD: PRODUCT PORTFOLIO
TABLE 067. PIRAMAL ENTERPRISES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. QUOTIENT SCIENCES: SNAPSHOT
TABLE 068. QUOTIENT SCIENCES: BUSINESS PERFORMANCE
TABLE 069. QUOTIENT SCIENCES: PRODUCT PORTFOLIO
TABLE 070. QUOTIENT SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. THERMO FISHER SCIENTIFIC INC. (PATHEON): SNAPSHOT
TABLE 071. THERMO FISHER SCIENTIFIC INC. (PATHEON): BUSINESS PERFORMANCE
TABLE 072. THERMO FISHER SCIENTIFIC INC. (PATHEON): PRODUCT PORTFOLIO
TABLE 073. THERMO FISHER SCIENTIFIC INC. (PATHEON): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. EMERGENT BIOSOLUTIONS INC.: SNAPSHOT
TABLE 074. EMERGENT BIOSOLUTIONS INC.: BUSINESS PERFORMANCE
TABLE 075. EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 076. EMERGENT BIOSOLUTIONS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. LONZA GROUP AG: SNAPSHOT
TABLE 077. LONZA GROUP AG: BUSINESS PERFORMANCE
TABLE 078. LONZA GROUP AG: PRODUCT PORTFOLIO
TABLE 079. LONZA GROUP AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. AURIGENE PHARMACEUTICAL SERVICES LTD: SNAPSHOT
TABLE 080. AURIGENE PHARMACEUTICAL SERVICES LTD: BUSINESS PERFORMANCE
TABLE 081. AURIGENE PHARMACEUTICAL SERVICES LTD: PRODUCT PORTFOLIO
TABLE 082. AURIGENE PHARMACEUTICAL SERVICES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. PCI PHARMA SERVICES: SNAPSHOT
TABLE 083. PCI PHARMA SERVICES: BUSINESS PERFORMANCE
TABLE 084. PCI PHARMA SERVICES: PRODUCT PORTFOLIO
TABLE 085. PCI PHARMA SERVICES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. HERMES PHARMA: SNAPSHOT
TABLE 086. HERMES PHARMA: BUSINESS PERFORMANCE
TABLE 087. HERMES PHARMA: PRODUCT PORTFOLIO
TABLE 088. HERMES PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. PYRAMID LABORATORIES INC: SNAPSHOT
TABLE 089. PYRAMID LABORATORIES INC: BUSINESS PERFORMANCE
TABLE 090. PYRAMID LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 091. PYRAMID LABORATORIES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 092. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 093. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 094. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY SERVICE
FIGURE 012. PRE-FORMULATION SERVICES MARKET OVERVIEW (2016-2028)
FIGURE 013. FORMULATION OPTIMIZATION MARKET OVERVIEW (2016-2028)
FIGURE 014. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY APPLICATION
FIGURE 015. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 016. GENETIC DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 017. NEUROLOGY MARKET OVERVIEW (2016-2028)
FIGURE 018. INFECTIOUS DISEASES MARKET OVERVIEW (2016-2028)
FIGURE 019. RESPIRATORY MARKET OVERVIEW (2016-2028)
FIGURE 020. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY DOSAGE FORM
FIGURE 023. INJECTABLE MARKET OVERVIEW (2016-2028)
FIGURE 024. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 025. TOPICAL MARKET OVERVIEW (2016-2028)
FIGURE 026. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 027. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)